"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 1 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 3 | 2 | 5 |
| 2005 | 4 | 2 | 6 |
| 2006 | 3 | 2 | 5 |
| 2007 | 3 | 2 | 5 |
| 2008 | 2 | 4 | 6 |
| 2009 | 4 | 3 | 7 |
| 2010 | 3 | 3 | 6 |
| 2011 | 2 | 4 | 6 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 0 | 3 |
| 2014 | 11 | 4 | 15 |
| 2015 | 8 | 2 | 10 |
| 2016 | 7 | 1 | 8 |
| 2017 | 3 | 3 | 6 |
| 2018 | 3 | 2 | 5 |
| 2019 | 5 | 3 | 8 |
| 2020 | 3 | 6 | 9 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 9 | 9 |
| 2024 | 7 | 2 | 9 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Ibraheem O, Ibikunle PD, Gabriel-Ajobiewe RAO, Oyeniran OH, Sodipe GO, Komolafe TR, Komolafe K, Oyewole OT, Ogwa EC, Jeje TO. Bacillus subtilis 7A Enhances the Nutritional Quality of Velvet Bean (Mucuna pruriens Linn.) Seeds and Potentiates Its Role in the Management of Type II Diabetes Mellitus. J Food Sci. 2025 Aug; 90(8):e70446.
-
Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, Kaelber DC, Xu R. Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study. J Alzheimers Dis. 2025 Aug; 106(4):1509-1522.
-
Sobhani NC, Huang Y, Venkatesh KK, Wright JD, Friedman AM, Wen T. Diabetes Technology Use in Pregnancies with Type 1 Diabetes in the United States from 2009 to 2020. Am J Perinatol. 2026 Mar; 43(4):453-460.
-
Mousavi M, Moridi Farimani M, Kashfi K, Ghasemi A. Antidiabetic Potential of Sophora Species: Mechanisms, Bioactive Constituents, and Therapeutic Prospects. Planta Med. 2025 Sep; 91(10-11):546-557.
-
Farahani A, Farahani A, Kashfi K, Ghasemi A. Inhibition of hepatic gluconeogenesis in type 2 diabetes by metformin: complementary role of nitric oxide. Med Gas Res. 2025 Dec 01; 15(4):507-519.
-
Brai B, Amosun B, Komolafe T, Joseph R, Komolafe K. In Vitro Antidiabetic Potential and Influence of Neem Oil Extract on Biochemical Indices of Toxicity Following Sub-Acute Administration in Rats. Niger J Physiol Sci. 2025 Jan 14; 39(1):77-85.
-
Brai BIC, Joseph RO, Komolafe TR, Amosun BE, Crown OO, Komolafe K, Ogungbe IV. Neem seed oil ameliorates diabetic phenotype by suppressing redox imbalance, dyslipidaemia and pro-inflammatory mediators in a rodent model of type 2 diabetes. Arch Physiol Biochem. 2025 Jun; 131(3):351-365.
-
Vaishnav MS, Kumari N, Srikanta S, Simha V, Krishnaswamy PR, Bhat N. Truncated Albumins as Novel Surrogate Biomarkers in Diabetes Therapy: Epiphenomena and Potential Clinical Applications. Metab Syndr Relat Disord. 2024 Dec; 22(10):743-752.
-
Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024 Dec; 20(12):8661-8672.
-
Davidson MB. Glycaemic treatment of newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2024 Nov; 26(11):5492-5493.